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Objectives This study sought to compare the survival of asymptomatic patients with previous revascularization and isch-
emia, who subsequently underwent repeat revascularization or medical therapy (MT).
Background Coronary artery disease is progressive and recurring; thus, stress myocardial perfusion scintigraphy (MPS) is
widely used to identify ischemia in patients with previous revascularization.
Methods Of 6,750 patients with previous revascularization undergoing MPS between January 1, 2005, and December 31,
2007, we identified 769 patients (age 67.7  9.5 years; 85% men) who had ischemia and were asymptomatic.
A propensity score was developed to express the associations of revascularization. Patients were followed up
over a median of 5.7 years (interquartile range: 4.7 to 6.4 years) for all-cause death. A Cox proportional hazards
model was used to identify the association of revascularization with all-cause death, with and without adjust-
ment for the propensity score. The model was repeated in propensity-matched groups undergoing MT versus re-
vascularization.
Results Among 769 patients, 115 (15%) underwent revascularization a median of 13 days (interquartile range: 6 to
31 days) after MPS. There were 142 deaths; mortality with MT and revascularization were 18.3% and
19.1% (p  0.84). In a Cox proportional hazards model (chi-square test  89.4) adjusting for baseline char-
acteristics, type of previous revascularization, MPS data, and propensity scores, only age and hypercholes-
terolemia but not revascularization were associated with mortality. This result was confirmed in a
propensity-matched group.
Conclusions Asymptomatic patients with previous revascularization and inducible ischemia on MPS realize no survival benefit
from repeat revascularization. In this group of post-revascularization patients, an ischemia-based treatment
strategy did not alter mortality. (J Am Coll Cardiol 2013;61:1616–23) © 2013 by the American College of
Cardiology FoundationAsymptomatic (silent) ischemia is common among pa-
tients with coronary artery disease (CAD) (1) and is
associated with adverse outcomes (2). Patients with
previous revascularization are prone to both recurrent
ischemia and coronary events (due to progression of
native coronary disease and/or graft closure and resteno-
sis), which are often silent. Based on the ability of
single-photon emission computed tomography (SPECT)
to predict outcomes post-coronary artery bypass graft
(CABG) (3,4), the appropriate-use criteria have deemed
functional testing to be appropriate for asymptomatic
patients 5 years after CABG but still uncertain for
symptomatic patients with previous percutaneous co-
onary intervention (PCI) or 5 years after CABG
5). Nonetheless, testing is often performed despite this
ncertainty.
See page 1624
Although the detection of silent ischemia identifies
patients at risk, the more controversial aspect relates to
whether this risk is responsive to treatment. Initial
reports emphasized that the recognition of this entity was
important because either medical therapy (MT) or revas-
cularization have been linked to improved survival (6,7).
Nonetheless, in the post-revascularization population,
our recent work found no survival benefit from the use ofsuch a strategy using stress echocardiography (8). These
findings seemed consistent with the recent COURAGE
(Clinical Outcomes Utilizing Revascularization and Ag-
gressive Drug Evaluation) trial, which found that a
strategy of initial PCI with aggressive MT has no survival
benefit over aggressive MT alone in patients with
angiographically documented CAD (9), irrespective of
extent of baseline perfusion defect (10). These findings
are discordant with observational data, which indicate
that myocardial perfusion scintigraphy (MPS)-identified
inducible ischemia is associated with improved survival
with revascularization in patients without previous myo-
cardial infarction or revascularization (11,12). Accord-
ingly, because the usefulness of functional testing for
symptomatic patients is well established (5), we hypoth-
esized that repeat revascularization in asymptomatic
post-revascularization patients who had MPS evidence of
ischemia would improve their outcome. Thus, the aim of
the current study was to define the benefit of repeat
revascularization in this setting, after adjustment for
baseline characteristics, type of previous revasculariza-
tion, and size of inducible perfusion defects.
Methods
Study population. We identified 6,750 consecutive pa-
tients with a history of revascularization (CABG or PCI)
who underwent exercise or adenosine stress MPS between
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metabolic equivalents; SBP  systolic blood pressure; SPECT  single-photon emission computed
tomography.
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31, 2007. Symptomatic patients
and/or those without inducible
ischemia on SPECT MPS were
excluded, leaving a final study
population of 769 patients (age
67.7  9.5 years; 85% men) who
were followed up over a median
of 5.7 years (interquartile range
[IQR]: 4.7 to 6.4 years) for all-
cause death. The study was ap-
proved by the institutional review
board of the Cleveland Clinic.
For the purpose of this study,
patients were separated into
those undergoing MT (n 
654) and those undergoing re-
vascularization (n  115). The
median time to repeat revascu-
larization after SPECT scan
was 13 days (IQR: 6 to 31
days); the majority (n  103)
underwent revascularization within
0 days or less, another 11 had revascularization within 6 months,
nd 1 underwent revascularization within 1 year. These groups
ere compared by using a propensity score (as discussed in the
tatistical Analysis section) to compensate for nonrandom
eferral to revascularization.
tress testing. Exercise stress testing was performed in
23 patients (42%) who were able to exercise. Exercise
apacity was estimated in metabolic equivalents, and
eart rate (HR) and blood pressure responses were
ecorded. The chronotropic response index was calculated
ccording to the formula using HR values: (peak HR – resting
R)/([220  age] – resting HR), where HR is given in
eats per min. A low chronotropic response index (0.8)
n a patient who is not receiving beta-blocker therapy is
ssociated with an increased likelihood of CAD and a
igher risk of death.
PECT methods. Images were acquired in accordance
ith the American Society of Nuclear Cardiology guide-
ines for gated SPECT single- or 2-day technetium-99m
racer (tetrofosmin) protocols (13). We used a 17-
egment model of the left ventricle to semiquantitatively
core stress and rest perfusion images by using standard
oftware (4D-MSPECT, University of Michigan Medi-
al Center, Ann Arbor, Michigan) (14,15). Each segment
as scored by consensus of 2 observers who used a
-point scoring system. On the basis of the overall
valuation, including the number and severity of segmen-
al scores, we identified the study as negative or positive
or ischemia.
The summed stress and rest scores were obtained by
dding the scores of the 17 segments of the respective
mages (14,15). The sum of the differences between each
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CI  confidence interval
CPH  Cox proportional
hazards
HR  heart rate
IQR  interquartile range
LVEF  left ventricular
ejection fraction
MPS  myocardial
perfusion scintigraphy
MT  medical therapy
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomographyf the 17 segments was defined as the summed differenceBaseline Characteristics of All PatientsTable 1 Baseline Characteristics of All Patients
Covariate
Medical Therapy
(n  654)
Revascularization
(n  115) p Value
Age 68 9.5 66 9.7 0.07
Male (%) 551 (84) 102 (88) 0.34
Follow-up duration (yrs) 5.2 1.6 5.3 1.5 0.75
Risk factors
Obesity 257 (39) 51 (44) 0.31
Diabetes mellitus 213 (33) 41 (36) 0.51
Current smoking of CAD 292 (45) 54 (47) 0.61
Hypertension 574 (88) 95 (83) 0.13
Hypercholesterolemia 607 (93) 103 (90) 0.23
Family history of CAD 47 (42) 317 (41) 0.97
SBP (mm Hg) 138 19 137 20 0.74
Hypothyroidism 39 (6) 8 (7) 0.68
Chronotropic response index 0.50 0.38 0.60 0.4 0.036
Aortic stenosis 16 (2) 6 (5) 0.1
Congestive heart failure 63 (10) 10 (9) 0.75
Transient ischemic attack 10 (1.5) 7 (6) 0.0022
Peripheral vascular disease 73 (11) 17 (15) 0.27
Atrial fibrillation 51 (8) 12 (10) 0.34
Ventricular fibrillation 22 (3.2) 7 (6.3) 0.90
Previous revascularizations 2 1 2 1 0.35
CABG 237 (36) 40 (35) 0.76
Time after last
revascularization (yrs)
5.4 5.4 5.0 5.6 0.18
Stress results
Exercise stress 265 (41) 58 (50) 0.047
Maximum heart rate 112.2 33.5 120 34 0.026
Percent predicted
maximum HR
73 21 77 23 0.08
Maximum SBP 159 29 165 36 0.085
Rate-pressure product 18,486 8,098 20,841 9,463 0.023
Exercise capacity (METs) 9.2 2 8.7 2 0.15
SPECT results
Summed stress score 10 7 12 8 0.004
Summed rest score 4 6 4 5 0.13
Summed difference score 6 5 8 6 0.0001
Ejection fraction (%) 68 2.7 57 12 0.43
Values are mean  SD or n (%).
CABG  coronary artery bypass graft; CAD  coronary artery disease; HR  heart rate; METs Features Associated With RevascularizationTable 2 Features Associated With Revascularization
Covariate Beta Coefficient Wald p Value
Maximum rate-pressure product
(per 1,000)
0.168 8.148 0.004
Transient ischemic attack 3.611 8.060 0.005
Summed difference score 0.097 6.690 0.010
Diabetes mellitus 0.976 4.231 0.040
Atrial fibrillation 1.588 4.029 0.045
Hypothyroidism 1.838 3.581 0.058
Ventricular fibrillation 3.137 3.555 0.059
Congestive heart failure 2.297 3.084 0.079
Male 1.585 2.930 0.087
Nonsignificant associations with revascularization included age, non–diabetesmellitus risk factors,
comorbidities (chronic renal failure, cancer, chronic lung disease), exercise capacity, previous
CABG and number of previous revascularizations, left ventricular function (ejection fraction, severe
left ventricular dysfunction and ischemic cardiomyopathy), sum rest score, valve disease, vascular
disease (peripheral, cerebrovascular, aortic), and arrhythmias.
Continued in the next column
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of these variables incorporate the extent and severity of
perfusion defects, which independently add prognostic
information (16).
Figure 1
Survival of Propensity-Matched Subjects
Undergoing Medical Therapy or Revascularization,
Adjusted for Age, Sex, and Ejection Fraction
Neither therapy (hazard ratio [HR]: 0.91 [95% confidence interval (CI): 0.50 to 1.66];
p  0.77) nor male (HR: 1.30 [95% CI: 0.62 to 2.73]; p  0.48) showed an
association with survival. Survival was associated with age (HR: 1.06 [95% CI:
1.02 to 1.11]; p  0.002) and ejection fraction (HR: 0.98 [95% CI: 0.95 to
0.99]; p  0.04).
ContinuedTable 3 Continued
Covariate
Medical Therapy
(n  115)
Revascularization
(n  115)
p
Value
Chronic pulmonary
disease
6 (5) 5 (4) 0.76
Chronotropic response
index
1 (0.9) 2 (2) 0.95
End-stage renal disease 4 (3) 3 (3) 0.95
Hyperlipidemia 106 (92) 103 (90) 0.47
Hyperthyroidism 1 (0.9) 1 (0.9) 0.95
Hypothyroidism 9 (8) 8 (7) 0.06
Peripheral vascular
disease
16 (14) 17 (15) 0.85
Sleep apnea 6 (5) 3 (3) 0.72
Syncope/near-syncope 5 (4) 6 (5) 0.76
No. of previous
revascularizations
2 1.5 2 1.2 0.13
Previous CABG 52 (45) 40 (35) 0.11
Summed stress score 10 7 12 8 0.06
Summed rest score 5 6 4 5 0.13
SDS 5 4 8 6 0.0001
Time between
catheterization and
last stress test (days)
303 143 233 151 0.06
Values are mean  SD or n (%).
CAD coronary artery disease; CVA cardiovascular accident; DBP diastolic blood pressure;
V  left ventricular; SDS  summed difference score; SVT  supraventricular tachycardia; TIA 
ransient ischemic attack; V-FIB  ventricular fibrillation; VT  ventricular tachycardia; other
bbreviations as in Table 1.Characteristics of the Matched PatientsFrom M dical Therapy Versus RevascularizationTable 3 Charact ristic of the Matched PatientsFrom Medical Therapy Versus Revascularization
Covariate
Medical Therapy
(n  115)
Revascularization
(n  115)
p
Value
Ejection fraction 0.57 0.12 0.57 0.12 0.87
Follow-up time (yrs) 5.1 1.7 5.3 1.5 0.56
Interval between last
revascularization and
stress test (yrs)
5.3 4.8 5.0 5.6 0.14
Male 91 (79) 101 (88) 0.08
Age (yrs) 69 7.5 66 10 0.062
Exercise test (%) 42 (37) 58 (50) 0.03
Obesity 49 (43) 51 (44) 0.8
Maximum heart rate 109 34 120 35 0.03
Maximum SBP (mm Hg) 158 30 165 36 0.12
Maximum DBP (mm Hg) 83 12 86 13 0.15
Maximum rate-pressure
product
17,975 8,393 20,842 9,464 0.03
Exercise time (min) 6.6 0.3 6.9 1.9 0.29
Exercise capacity (METs) 9 2 9 2 0.36
HR recovery 8 11 10 10 0.12
Percent predicted
maximum HR (%)
71 22 77 23 0.07
Resting SBP 138 20 137 20 0.78
Resting DBP 81 11 81 11 0.92
Chronotropic response
index
0.47 0.39 0.59 0.4 0.05
Diabetes mellitus 37 (32) 41 (36) 0.54
Current smoking 48 (42) 54 (47) 0.39
Hypertension 105 (91) 95 (83) 0.05
Hypercholesterolemia 107 (93) 103 (90) 0.35
Family history of CAD 38 (33) 47 (41) 0.18
Arrhythmia 0 3 (3) 0.25
Atrial fibrillation 9 (8) 12 (10) 0.35
Atrial flutter 0 1 (0.9) 0.95
Nonsustained VT 2 (2) 0 0.16
SVT 1 (0.9) 2 (2) 1
V-FIB 0 5 (4) 0.06
VT 3 (3) 2 (2) 0.95
Aortic aneurysm 6 (5) 3 (3) 0.5
Aortic insufficiency 8 (7) 4 (3) 0.37
Aortic stenosis 2 (2) 6 (5) 0.28
Mitral regurgitation 20 (17) 12 (10) 0.13
Mitral valve prolapse 2 (2) 0 0.5
Tricuspid regurgitation 5 (4) 3 (3) 0.72
Nonrheumatic valve
disease
1 (0.9) 4 (3) 0.37
Asthma 4 (3) 5 (4) 0.95
Cancer 11 (10) 15 (13) 0.4
Cardiac arrest 1 (0.9) 4 (3) 0.37
Cardiomyopathy 3 (3) 2 (2) 0.95
Carotid atherosclerosis 27 (23) 21 (18) 0.33
CVA 9 (8) 4 (3) 0.25
TIA 2 (2) 7 (6) 0.17
Heart failure 14 (12) 10 (9) 0.39
Ischemic cardiomyopathy 3 (3) 1 (0.9) 0.62
Severe LV dysfunction 1 (0.9) 1 (0.9) 0.95
Complete heart block 1 (0.9) 0 0.95
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5.7 years (IQR: 4.7 to 6.4 years) for the primary endpoint
(all-cause mortality). All-cause death was defined as any
death during the follow-up period, and the deaths were
confirmed by review of death certificate and hospital
chart or physician records. Of 769 patients, 2 were lost
during follow-up because they were followed up by others
rather than by the Cleveland Clinic healthcare system
(99.7% follow-up rate). The survival status of all patients,
including the 2 patients lost to follow-up, was confirmed
by using the Social Security Death Index at the end of
follow-up.
Statistical analysis. Continuous variables are described as
ean  SD. Between-group comparisons were performed
y using the Student t test for continuous variables and a
hi-square test for categorical variables. Analyses were
erformed by using standard statistical software (SPSS
ersion 18.0 [IBM, Chicago, Illinois] and SAS version 9.3
SAS Institute, Cary, North Carolina]; S-plus Release 2,
nsightful Corporation, Seattle, Washington).
The first step in the analysis was based on developing
propensity model, using a nonparsimonious logistic
egression to summarize factors associated with the
ecision to refer patients to revascularization versus MT
17,18); all factors known to influence this referral
ecision were used in the analysis (19 –21). This score
as used to reduce the bias introduced by nonrandomized
eferral patterns to revascularization in clinical practice in
ways. This score was used as the basis for a propensity-
atched survival analysis. In addition, to ensure that
hese results were not due to loss of study power by this
election process, we analyzed the full cohort with the
ncorporation of this score into a Cox proportional
azards (CPH) model as a covariate (22).
Survival analyses were performed by using CPH mod-
ling to examine the association of post-MPS treatment
nd event-free survival time after adjustment for baseline
atient characteristics and potential confounders. Our
rimary study hypothesis was directly addressed in these
PH models by examining the following: 1) whether
Cox Proportional Hazards Model for Aggregate Clinical Risk ScoreTable 4 Cox Proportional Hazards Model for Aggregate Clinical
Variable  p Value Hazar
End-stage renal disease 1.4299 0.0026 4.1
Diabetes mellitus 0.1832 0.32 1.2
Appropriateness score 0.0978 0.11 1.1
History of previous revascularization 0.1237 0.097 0.8
Female 4.8052 0.0041 0.0
Age 0.0206 0.32 1.0
Age  sex 0.0597 0.011 1.0
Smoking 0.4968 0.0057 1.6
Aortic stenosis 0.8266 0.14 0.4
Cancer 0.6821 0.0036 1.9
Anemia 0.6255 0.047 1.8Overall model: Wald chi-square test  88; p  0.0001; Score test  94; p  0.0001post-MPS revascularization was associated with im-
proved survival time; and 2) whether an interaction was
present between post-MPS revascularization and several
predefined imaging metrics, including percent myocar-
dium ischemic, percent myocardium fixed, and left ven-
tricular ejection fraction (LVEF). To avoid model over-
fitting, we developed an initial CPH model incorporating
baseline clinical, historical, and demographic data into a
single composite score summarizing baseline patient risk.
We pre-specified this model to include end-stage renal
disease, diabetes mellitus, history of previous revascular-
ization, age, smoking history, sex, appropriateness score,
history of cancer, history of anemia, and aortic stenosis.
Predicted probability of death for each subject was
extracted from the model and used to represent the
medical risk in subsequent models.
Based on the previous report that compared the effect of
revascularization versus MT in asymptomatic patients (23),
he expected hazard ratio was 0.34. In the setting of a
-tailed alpha of 0.05 and power of 0.90, the required
ample size was 117.
esults
atient characteristics. Table 1 shows the comparison of
baseline characteristics between the 654 patients who un-
derwent MT and the 115 who underwent revascularization.
There were few differences in baseline characteristics be-
tween these 2 groups. Patients who underwent revascular-
ization had a higher maximum HR and rate-pressure
product during stress testing, probably because of a higher
frequency of exercise testing in this group. In addition,
patients who had post-MPS revascularization were more
likely to have a history of transient ischemic attack, ventric-
ular fibrillation, pulmonary embolism, and lower exercise
capacity (metabolic equivalents), as well as a greater total
ischemic burden as determined by a higher SDS.
The time between the previous revascularization and the
index MPS in patients who received MT was similar to
patients referred for revascularization (5.4  5.4 years vs.
Score
o Lower 0.95 Confidence Interval Upper 0.95 Confidence Interval
1.646 10.604
0.837 1.724
0.979 1.243
0.764 1.023
0.001 0.218
0.980 1.063
1.014 1.111
1.156 2.337
0.147 1.302
1.250 3.131
1.008 3.467Risk
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April 16, 2013:1616–23 Repeat Revascularization and Outcome5.0  5.6 years; p  0.18), and the type of previous
evascularization was similar (p  0.76).
utcome events. Over the 5.7-year follow-up period, 142
atients died. Mortality with MT was 18.3% compared with
9.1% with revascularization (p  0.84).
ropensity-matched analysis. Multiple factors (Table 2)
ssociated with referral to revascularization after MPS were
ncluded in the propensity model (chi-square test  79.6; c
ndex  0.842; p  0.008). Propensity-matched groups
ndergoing MT compared with revascularization (Table 3)
howed no difference in survival (chi-square test  13.603;
 0.767) (Fig. 1).
A clinical risk score was developed by using a CPH model
global chi-square test  88; p  0.0001) (Table 4). The
ajor predictors in this model included a history of cancer,
nemia, end-stage renal disease, and smoking as well as
atient age and sex. The latter 2 variables also interacted in
he model. Predicted probabilities of death for each subject
rom this model were used in subsequent CPH models as a
linical risk score.
Unadjusted comparison of all patients (chi-square test 
0.1; p  0.69) showed no association of revascularization
ith mortality (Fig. 2A). Mortality was associated with age
hazard ratio: 1.07 [95% confidence interval (CI): 1.04 to
.09]; p  0.0001) and hypercholesterolemia (hazard ratio:
.34 [95% CI: 1.44 to 3.80]; p  0.001).
ultivariable modeling. A CPH model was used to
dentify the association of revascularization with all-cause
eath, with adjustment for the clinical risk score and the
ropensity score. In the final CPH model adjusted for
ropensity score (Wald chi-square test  89.6; p 
.0001) (Table 5), clinical risk score and the use of
harmacological stress were the most important predic-
ors of outcome. None of the imaging variables were
ignificant predictors of all-cause death. Percent myocar-
ium ischemic, percent myocardium fixed, and LVEF did
ot significantly interact with post-MPS revasculariza-
ion in the final CPH model. Adjusted comparison of all
atients showed no association of revascularization with
ortality (p  0.53) (Fig. 2B).
Finally, we examined limited CPH models to explore
he association of combinations of 4 covariates with
ardiac death as the endpoint (42 total cardiac deaths).
fter adjusting for clinical risk score and the use of
harmacological stress, neither percent myocardium ab-
ormal nor LVEF were significant predictors in the CPH
odel (p  0.35 and p  0.36, respectively; global
hi-square test  36.7).
iscussion
lthough the appropriateness of MPS as a surveillance tool
o assess for residual or recurrent ischemia post-
evascularization is uncertain, it is often used routinely for
his purpose (5). The underlying assumption is that thedentification of post-revascularization ischemia would be
n adverse prognostic finding, and the corollary belief is that
epeat revascularization would be of benefit in reducing
ubsequent clinical events such as myocardial infarction or
eath. In this study, asymptomatic patients with MPS-
roven ischemia after previous revascularization (PCI or
ABG) who underwent repeat revascularization realized no
urvival benefit over those who received MT either in
Figure 2 Survival of All Patients Undergoing
Medical Therapy or Revascularization
(A) Unadjusted survival. There was no association of revascularization with
mortality (HR: 0.90 [95% CI: 0.55 to 1.48]; p  0.69). (B) Adjusted sur-
vival. There was no association of revascularization with mortality (HR: 1.18
[95% CI: 0.70 to 2.00]; p  0.53). Abbreviations as in Figure 1.
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analyses. In contrast, age and hypercholesterolemia were
strongly associated with all-cause mortality.
Many studies have examined the clinical outcomes de-
rived from myocardial revascularization in patients under-
going MPS. Generally, these studies have examined pa-
tients without CAD (11,12), or patients with a history of
CAD with or without previous revascularization (4), but
they have not discriminated symptomatic from asymptom-
atic patients. This distinction is important because revascu-
larization can be readily defended in symptomatic patients.
The discordant findings between these observations and our
current result may very likely reflect differences in the study
populations.
In the recently published baseline nuclear substudy of the
COURAGE trial (10), patients with extensive inducible
ischemia at baseline (of whom 85% were symptomatic)
did not seem to have a greater event rate with optimal MT
alone compared with revascularization. In contrast, Ha-
chamovitch et al. (24) reported that post-MPS treatment
and subsequent survival were dictated by the interaction
between the use of early revascularization, percentage of
ischemic myocardium, and history of previous CAD. In the
absence of previous CAD, a greater extent of ischemia was
associated with greater improvement in all-cause mortality
risk with early revascularization compared with MT; in the
presence of little or no ischemia, early revascularization was
associated with approximately 50% greater risk than MT.
These findings are concordant with studies showing revas-
cularization to be an effective treatment for patients with
extensive coronary disease burden (25–27). The novelty of
our current work is that it focused on application in
asymptomatic post-revascularization patients with ischemia,
a group that would be a subpopulation in the previous
studies.
In asymptomatic patients, such a decision would have to
be justified prognostically, and the evidence to support this
action seems controversial. In the SWISSI II (Swiss Inter-
ventional Study on Silent Ischemia Type II) trial (28), PCI
improved survival from cardiac death, as a secondary end-
point, in patients with silent ischemia after a recent myo-
Cox Proportional Hazards Model: Aggregate Clinical Risk Score WiTable 5 Cox Proportional Hazards Model: Aggregate Clinical R
Variable  p Value Hazar
Percent myocardium ischemic 0.0005 0.9875 1.0
History of previous revascularization 0.1387 0.0702 1.0
Use of post-MPS revascularization 0.1688 0.5293 1.1
Percent myocardium fixed 0.0114 0.5220 1.0
Left ventricular ejection fraction 0.3556 0.1238 0.7
Use of pharmacological stress 1.4521 0.0001 4.2
Clinical risk score 0.6363 0.0001 1.8
Propensity score 0.5172 0.5928 1.6
Overall model: Wald chi-square test  89.6; p  0.0001; Score test  99; p  0.00
MPS  myocardial perfusion scintigraphy.cardial infarction. However, in another substudy of 283asymptomatic patients from the COURAGE trial (23), of
whom 13% to 14% of patients were post-revascularization
and 76% had 5% ischemic myocardium, the addition of
PCI to optimal MT did not significantly decrease composite
outcomes or mortality. Our current study, limited to asymp-
tomatic post-revascularization patients, is in agreement with
this finding.
Study limitations. This study was a single-site, observa-
tional trial and as such has inherent flaws relating to
selection bias, spurious observations, unmeasured covariates,
and nonrandom allocation to treatment (19,21,29–31). We
sought to avoid these problems by using standardized
templates in the electronic medical record and incorporating
a propensity model with the multivariable analysis.
In this study of 769 patients, 115 (15%) underwent
revascularization, and there were 142 deaths, 22 of whom
were in the revascularized group. As a result, the study was
only adequately powered for relatively large effects, espe-
cially in relation to interactions. By using all-cause mortality
as the primary endpoint, we may have diluted a potential
benefit of intervention on cardiovascular outcome, although
in this population, we would expect cardiovascular causes of
death to predominate, and the avoidance of death certificate
diagnosis avoided misclassification bias. We did not differ-
entiate between revascularization performed with CABG
versus PCI; the efficacy of these 2 approaches may differ in
select patient subgroups (32).
Conclusions
Routine MPS in asymptomatic patients late after revas-
cularization is deemed to be of indeterminate appropri-
ateness. Our recent work has shown no survival benefit
from this approach (8) when using stress echocardiogra-
phy, but this observation is tempered by the limited
number of abnormal stress test results. In this MPS-
based study, our data found no evidence that repeat
revascularization provides a survival benefit, even in
patients with inducible ischemia. If invasive downstream
therapeutic responses do not alter survival even when
ischemia is present, it is difficult to justify using MPS to
aging Datacore With Imaging Data
o Lower 0.95 Confidence Interval Upper 0.95 Confidence Interval
0.962 1.040
0.749 1.010
0.700 2.00
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0.446 1.100
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0.252 11.16th Imisk S
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01investigate asymptomatic patients post-revascularization.
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